A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- You must have been diagnosed with non-small cell lung cancer.

- You must be able to visit the doctor's office weekly during the active treatment
period and as needed during the study follow-up period.

- You must be willing and able to swallow capsules.

- Your entry labs and medical tests must meet study requirements.

- You must be willing to have blood samples drawn and tissue samples obtained for gene
and protein testing.

Exclusion Criteria:

- You have received radiation within 2 weeks of study enrollment.

- You have previously received any anti-cancer drug therapy for non-small cell lung
cancer.

- You have an active infection or other serious condition.

- You take aspirin or aspirin-like medication regularly and are not able to stop taking
them for a few days during each cycle of chemotherapy.

- You have recently lost a significant amount of weight.